Skip to content

新闻稿

Illumina与Bio-Rad联合发布单细胞基因组测序解决方案,使复杂疾病研究更可靠

圣地亚哥与赫拉克勒斯,加利福尼亚州 --2017年1月9日-- Illumina公司 (纳斯达克股票代码:ILMN) Bio-Rad实验室公司 (NYSE:BIO) (纽约证券交易所市场代码:BIOb) 今日在JP摩根健康大会上发布了Illumina® Bio-Rad® Single-Cell Sequencing Solution该综合解决方案是单细胞分析的第一个新一代测序(NGS)工作流程,使研究人员能够在组织功能、病情进展和治疗反应方面深入探查个体细胞的协同作用。

Illumina® Bio-Rad® Single-Cell Sequencing Solution包括全新的ddSEQ Single-Cell Isolator(与NextSeq 500合照)(照片来源:Business Wire)

单细胞分析可深层探查个体细胞的基因表达,从而了解其在复杂组织中的功能。与以往任务艰巨且昂贵费时的流程不同,该解决方案能够对数以千计的个体细胞进行高通量测序。单细胞测序广泛用于人类发展与疾病研究中,能在该解决方案发布以后获益良多。

“单细胞基因组学能够以高得多的精度查看干细胞转变为神经元的过程,这些神经元在帕金森病和肌萎缩性脊髓侧索硬化症(也叫作卢·格里克症)中是缺失的,”洛杉矶雪松-西奈再生医学中心机构审查委员会主任Clive Svendsen博士说道。他的实验室试用了新平台,对用于神经退行性疾病建模的单细胞进行了基因测序

“使用此解决方案可以在群落中发现成熟比其他细胞更快的单细胞,让我们对疾病建立更好的模型,”雪松-西奈再生医学中心机构审查委员会项目科学家及主要研究员Ritchie Ho博士补充道。

该解决方案包括ddSEQ™ Single-Cell Isolator和SureCell™ WTA 3’Library Prep Kit。Bio-Rad最好的液滴分离技术,Droplet Digital™技术,可以对单细胞进行隔离和编制条形码,然后在Illumina的许多主要NGS仪器上进行下游测序。全面的工作流程解决方案包括使用BaseSpace® Informatics Suite、Illumina的云端基因组学计算环境进行初级和中级数据分析,使用流式细胞分析技术的领先公司FlowJo, LLC所开发的SeqGeq™进行高级数据分析和可视化处理。

“通过与Illumina之间的紧密合作,我们为单细胞分析开发了一套无缝的可扩展解决方案,”Bio-Rad数字生物学组执行副总裁兼总经理Annette Tumolo说。“我们很荣幸为研究界的细胞生物学同仁配备他们需要的工具来推动新的发现。”

“我们希望细胞生物学家接触到这些降低单细胞分析成本同时又易于使用的技术,让他们凭借获得的基因表达信息推动复杂疾病的研究,”Illumina应用基因组学部副总裁兼总经理Rob Brainin说。“与Bio-Rad的合作让我们把此项技术快速引入市场,使我们的客户能够解码基因组而改善人类健康。”

Illumina® Bio-Rad® Single-Cell Sequencing Solution将在二月上旬发货。了解更多有关仪器、试剂和工作流程的信息,请访问www.bio-rad.com/ddSEQ

仅供研究使用。不得用于诊断。

关于Illumina

Illumina公司通过解码基因组而改善人类健康。我们注重创新,这使我们成为DNA测序和芯片技术的全球领导者,并为科研、临床和应用市场的客户提供服务。我们的产品应用在生命科学、肿瘤学、生殖保健、农业及其他新兴市场上。如欲了解更多信息,请访问:www.illumina.com或关注 @illumina。

关于Bio-Rad

Bio-Rad实验室公司(纽约证券交易所市场代码:BIO)(BIOb)为生命科学研究和临床诊断市场开发、制造并销售一系列创新型产品和解决方案。该公司以在大学与研究机构、医院、公共卫生以及商业实验室,生物科技、制药和食品安全行业提供的高质量客户服务而著称。1952年创立的Bio-Rad总部位于加利福尼亚州的赫拉克勒斯,通过其全球运营的网络服务于100000多家研究与健康产业的客户。该公司全球员工超过8000名,在2015年的销售额超过20亿美元。如欲了解更多信息,请访问:www.bio-rad.com.

Illumina Forward-Looking Statements

This release contains forward-looking statements that involve risks and uncertainties, such as Illumina’s expectations regarding the launch of any products. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to further develop and commercialize our instruments and consumables and to deploy new products, services, and applications, and expand the markets, for our technology platforms; (ii) our ability to manufacture robust instrumentation and consumables; (iii) achievement and timing of the planned deconsolidation of GRAIL, Inc.’s financial results in our financial statements; (iv) our ability to successfully identify and integrate acquired technologies, products, or businesses; (v) our expectations and beliefs regarding future conduct and growth of the business and the markets in which we operate; (vi) challenges inherent in developing, manufacturing, and launching new products and services; and (vii) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.

Bio-Rad Forward-Looking Statements

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding plans to introduce new products and the opportunities that may result from such new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

查看新闻来源:http://www.businesswire.com/news/home/20170109006365/en/

来源:Illumina公司

Bio-Rad Laboratories公司
Tina Cuccia, Corporate Communications
510-724-7000
tina_cuccia@bio-rad.com

Illumina公司
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com

Media:
Gwen Gordon
858-882-6822
pr@illumina.com

Recent Articles

Veterans Find New Rewards at Illumina
Veterans Find New Rewards at Illumina
Opening Doors for Students and the Possibilities of a STEM Career
Opening Doors for Students and the Possibilities of a STEM Career
Let it Grow: A DNA Database for Plants, One Species at a Time
Let it Grow: A DNA Database for Plants, One Species at a Time